BioTime, Inc. and the California Institute for Regenerative Medicine Sign Distribution Agreement for GMP-Compliant Human Embryonic Stem Cell Lines ALAMEDA, Calif ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet needs, announced today the issuance of a ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has ...
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement with ...
BioTime, Inc. announced an agreement with the California Institute for Regenerative Medicine (CIRM) to make five clinical-grade human Embryonic Stem (hES) cell lines available to California-based ...
BioTime, Inc. (NYSE MKT: BTX) announced that the company has amended its license from the University of Utah to expand the field of use for which BioTime is licensed to produce and market products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback